1. Clinical Utility of Circulating Cell‐Free DNA as a Liquid Biopsy in Cats With Various Tumours.
- Author
-
Tagawa, Michihito, Hiroi, Hotaka, Nakano, Yuzuki, Morishita, Riyo, Kobayashi, Kosuke, and Sakai, Osamu
- Subjects
- *
TUMOR markers , *CELL-free DNA , *POLYMERASE chain reaction , *INVASIVE diagnosis , *VETERINARY medicine , *CAT diseases - Abstract
Only a limited number of tumour biomarkers are currently available in veterinary medicine, particularly in cats. Cell‐free DNA (cfDNA) is an extracellular DNA fragment released upon cell death and is considered a minimally invasive biomarker for the diagnosis and monitoring of various human malignancies. This study aimed to clarify the utility of circulating cfDNA as a liquid biopsy for various feline tumours. Plasma samples were collected from 44 cats with various tumours, 24 cats with other diseases and 10 healthy controls. A follow‐up study was conducted in three tumour‐bearing patients. All cfDNA concentrations were quantified via real‐time polymerase chain reaction (PCR), which provided short and long fragments of a newly identified feline LINE‐1 gene. We found that cfDNA levels were significantly higher in cats with various tumours than in those with other diseases or healthy controls. The cfDNA concentration was not correlated with serum amyloid A (SAA) levels. Cats with tumours exhibited elevated cfDNA levels that predicted tumour‐bearing with a sensitivity and specificity of 50.5% and 91.2%, respectively (AUC 0.736; p < 0.001). In lymphoma cases, cats with high cfDNA levels had significantly shorter survival times than those with low cfDNA levels (median: 33 days vs. 178 days; p = 0.003). In addition, the cfDNA levels of the three patients correlated with clinical status during follow‐up. Collectively, these findings indicate the potential of cfDNA as a useful biomarker for the diagnosis, therapeutic monitoring and prognostic assessment of tumours in cats. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF